<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39455963</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1477-3155</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>Journal of nanobiotechnology</Title><ISOAbbreviation>J Nanobiotechnology</ISOAbbreviation></Journal><ArticleTitle>Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years.</ArticleTitle><Pagination><StartPage>661</StartPage><MedlinePgn>661</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">661</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12951-024-02900-y</ELocationID><Abstract><AbstractText>Nanobodies (Nbs) are antibody fragments derived from heavy-chain-only IgG antibodies found in the Camelidae family as well as cartilaginous fish. Their unique structural and functional properties, such as their small size, the ability to be engineered for high antigen-binding affinity, stability under extreme conditions, and ease of production, have made them promising tools for diagnostics and therapeutics. This potential was realized in 2018 with the approval of caplacizumab, the world's first Nb-based drug. Currently, Nbs are being investigated in clinical trials for a broad range of treatments, including targeted therapies against PDL1 and Epidermal Growth Factor Receptor (EGFR), cardiovascular diseases, inflammatory conditions, and neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. They are also being studied for their potential for detecting and imaging autoimmune conditions and infectious diseases such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A variety of methods are now available to generate target-specific Nbs quickly and efficiently at low costs, increasing their accessibility. This article examines these diverse applications of Nbs and their promising roles. Only the most recent articles published in the last five years have been used to summarize the most advanced developments in the field.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Columbia University, New York City, NY, USA. ei2169@columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leong</LastName><ForeName>Kam W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Columbia University, New York City, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Nanobiotechnology</MedlineTA><NlmUniqueID>101152208</NlmUniqueID><ISSNLinking>1477-3155</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061905">Single-Domain Antibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061905" MajorTopicYN="Y">Single-Domain Antibodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CRISPR</Keyword><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Cardiovascular</Keyword><Keyword MajorTopicYN="N">Diagnosis</Keyword><Keyword MajorTopicYN="N">Display techniques</Keyword><Keyword MajorTopicYN="N">Infectious-disease</Keyword><Keyword MajorTopicYN="N">Nanobody</Keyword><Keyword MajorTopicYN="N">Nanobody-imaging</Keyword><Keyword MajorTopicYN="N">Neurogenerative</Keyword><Keyword MajorTopicYN="N">Neurogenerative diseases</Keyword><Keyword MajorTopicYN="N">Production</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>23</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39455963</ArticleId><ArticleId IdType="doi">10.1186/s12951-024-02900-y</ArticleId><ArticleId IdType="pii">10.1186/s12951-024-02900-y</ArticleId><ArticleId IdType="pmc">PMC11515141</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kang W, et al. Nanobody conjugates for targeted cancer therapy and imaging. Technol Cancer Res Treat. 2021;20:15330338211010116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8111546</ArticleId><ArticleId IdType="pubmed">33929911</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunz S, et al. NANOBODY((R)) molecule, a giga medical tool in nanodimensions. Int J Mol Sci. 2023;24(17):13229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10487883</ArticleId><ArticleId IdType="pubmed">37686035</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin BK, et al. NANOBODIES®: a review of diagnostic and therapeutic applications. Int J Mol Sci. 2023;24(6):5994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10057852</ArticleId><ArticleId IdType="pubmed">36983063</ArticleId></ArticleIdList></Reference><Reference><Citation>Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–97.</Citation><ArticleIdList><ArticleId IdType="pubmed">23495938</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvador JP, Vilaplana L, Marco MP. Nanobody: outstanding features for diagnostic and therapeutic applications. Anal Bioanal Chem. 2019;411(9):1703–13.</Citation><ArticleIdList><ArticleId IdType="pubmed">30734854</ArticleId></ArticleIdList></Reference><Reference><Citation>De Genst E, et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci. 2006;103(12):4586–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1450215</ArticleId><ArticleId IdType="pubmed">16537393</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell LS, Colwell LJ. Analysis of nanobody paratopes reveals greater diversity than classical antibodies. Protein Eng Des Sel. 2018;31(7–8):267–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6277174</ArticleId><ArticleId IdType="pubmed">30053276</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovcevska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs. 2020;34(1):11–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985073</ArticleId><ArticleId IdType="pubmed">31686399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-López E, Schuhmacher AJ. Transportation of single-domain antibodies through the blood–brain barrier. Biomolecules. 2021;11(8):1131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394617</ArticleId><ArticleId IdType="pubmed">34439797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications. Int J Nanomedicine. 2016;11:3287–303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4959585</ArticleId><ArticleId IdType="pubmed">27499623</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J, et al. A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics. PLoS ONE. 2021;16(7): e0254944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8301669</ArticleId><ArticleId IdType="pubmed">34297759</ArticleId></ArticleIdList></Reference><Reference><Citation>Muyldermans S. A guide to: generation and design of nanobodies. FEBS J. 2021;288(7):2084–102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8048825</ArticleId><ArticleId IdType="pubmed">32780549</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinclair L, et al. Microbial community composition and diversity via 16S rRNA gene amplicons: evaluating the illumina platform. PLoS ONE. 2015;10(2): e0116955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4315398</ArticleId><ArticleId IdType="pubmed">25647581</ArticleId></ArticleIdList></Reference><Reference><Citation>Drengenes C, et al. Exploring protocol bias in airway microbiome studies: one versus two PCR steps and 16S rRNA gene region V3 V4 versus V4. BMC Genomics. 2021;22(1):3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7784388</ArticleId><ArticleId IdType="pubmed">33397283</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenstein M. Microbiology: making the best of PCR bias. Nat Methods. 2018;15(5):317–20.</Citation><ArticleIdList><ArticleId IdType="pubmed">29702634</ArticleId></ArticleIdList></Reference><Reference><Citation>Teymennet-Ramírez KV, Martínez-Morales F, Trejo-Hernández MR. Yeast surface display system: strategies for improvement and biotechnological applications. Front Bioeng Biotechnol. 2022; 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784408</ArticleId><ArticleId IdType="pubmed">35083204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolmar H, et al. Construction of semisynthetic shark vNAR yeast surface display antibody libraries. Methods Mol Biol. 2023;2702:227–43.</Citation><ArticleIdList><ArticleId IdType="pubmed">37679622</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda H, et al. VNAR development through antigen immunization of Japanese topeshark (Hemitriakis japanica). Front Bioeng Biotechnol. 2023; 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10522858</ArticleId><ArticleId IdType="pubmed">37771574</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdés-Tresanco MS, et al. Structural insights into the design of synthetic nanobody libraries. Molecules. 2022;27(7):2198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9000494</ArticleId><ArticleId IdType="pubmed">35408597</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno E, et al. Structure-based design and construction of a synthetic phage display nanobody library. BMC Res Notes. 2022;15(1):124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8966178</ArticleId><ArticleId IdType="pubmed">35351202</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T, et al. Construction of a humanized artificial VHH library reproducing structural features of camelid VHHs for therapeutics. Antibodies (Basel). 2022;11(1):10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8884020</ArticleId><ArticleId IdType="pubmed">35225868</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras MA, et al. Design and construction of a synthetic nanobody library: testing its potential with a single selection round strategy. Molecules. 2023;28(9):3708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10180287</ArticleId><ArticleId IdType="pubmed">37175117</ArticleId></ArticleIdList></Reference><Reference><Citation>Asaadi Y, et al. A comprehensive comparison between camelid nanobodies and single chain variable fragments. Biomarker Research. 2021;9(1):87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8642758</ArticleId><ArticleId IdType="pubmed">34863296</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukahara N, et al. An alpaca single-domain antibody (VHH) phage display library constructed by CDR shuffling provided high-affinity VHHs against desired protein antigens. Int Immunol. 2022;34(8):421–34.</Citation><ArticleIdList><ArticleId IdType="pubmed">35689594</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Yang D. Easily established and multifunctional synthetic nanobody libraries as research tools. Int J Mol Sci. 2022;23(3):1482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8835997</ArticleId><ArticleId IdType="pubmed">35163405</ArticleId></ArticleIdList></Reference><Reference><Citation>Salema V, Fernandez LA. Escherichia coli surface display for the selection of nanobodies. Microb Biotechnol. 2017;10(6):1468–84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5658595</ArticleId><ArticleId IdType="pubmed">28772027</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchanski T, et al. An improved yeast surface display platform for the screening of nanobody immune libraries. Sci Rep. 2019;9(1):382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6344588</ArticleId><ArticleId IdType="pubmed">30674983</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossotti MA, et al. Isolation and characterization of single-domain antibodies from immune phage display libraries. Methods Mol Biol. 2023;2702:107–47.</Citation><ArticleIdList><ArticleId IdType="pubmed">37679618</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon C, et al. Yeast surface display platform for rapid discovery of conformationally selective nanobodies. Nat Struct Mol Biol. 2018;25(3):289–96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839991</ArticleId><ArticleId IdType="pubmed">29434346</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Zhang J, Fang L. Next-generation sequencing and proteomics-enabled approach for rapid and high-throughput isolation of virus-neutralizing Nanobodies. In: Lozach P-Y, editor. Rift valley fever virus: methods and protocols. New York: Springer, US; 2024. p. 135–46.</Citation><ArticleIdList><ArticleId IdType="pubmed">39039411</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, et al. Construction of synthetic nanobody library in mammalian cells by dsDNA-based strategies*. ChemBioChem. 2021;22(20):2957–65.</Citation><ArticleIdList><ArticleId IdType="pubmed">34411391</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardon E, et al. A general protocol for the generation of Nanobodies for structural biology. Nat Protoc. 2014;9(3):674–93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297639</ArticleId><ArticleId IdType="pubmed">24577359</ArticleId></ArticleIdList></Reference><Reference><Citation>Egloff P, et al. Engineered peptide barcodes for in-depth analyses of binding protein libraries. Nat Methods. 2019;16(5):421–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116144</ArticleId><ArticleId IdType="pubmed">31011184</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufner P, Jermutus L, Minter RR. Harnessing phage and ribosome display for antibody optimisation. Trends Biotechnol. 2006;24(11):523–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17000017</ArticleId></ArticleIdList></Reference><Reference><Citation>Omidfar K, Daneshpour M. Advances in phage display technology for drug discovery. Expert Opin Drug Discov. 2015;10(6):651–69.</Citation><ArticleIdList><ArticleId IdType="pubmed">25910798</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y, et al. A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike. PLoS ONE. 2022;17(8): e0272364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9365158</ArticleId><ArticleId IdType="pubmed">35947606</ArticleId></ArticleIdList></Reference><Reference><Citation>Grahn AK, Allen GL, Kay BK. Efficient cloning of inserts for phage display by golden gate assembly. Methods Mol Biol. 2023;2702:191–203.</Citation><ArticleIdList><ArticleId IdType="pubmed">37679620</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim HT, et al. Exploring shark VNAR antibody against infectious diseases using phage display technology. Fish Shellfish Immunol. 2023;140: 108986.</Citation><ArticleIdList><ArticleId IdType="pubmed">37541634</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa H, et al. Synthesis of epitope-targeting nanobody based on native protein-protein interactions for FtsZ filamentation suppressor. Biotechnol J. 2023;18(11): e2300039.</Citation><ArticleIdList><ArticleId IdType="pubmed">37458140</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellmann C, et al. A one-step process for the construction of phage display scFv and VHH libraries. Mol Biotechnol. 2020;62(4):228–39.</Citation><ArticleIdList><ArticleId IdType="pubmed">31981039</ArticleId></ArticleIdList></Reference><Reference><Citation>Koide A, Koide S. Affinity maturation of single-domain antibodies by yeast surface display. Methods Mol Biol. 2012;911:431–43.</Citation><ArticleIdList><ArticleId IdType="pubmed">22886267</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth L, et al. Isolation of antigen-specific VHH single-domain antibodies by combining animal immunization with yeast surface display. Methods Mol Biol. 2020;2070:173–89.</Citation><ArticleIdList><ArticleId IdType="pubmed">31625096</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, et al. A fine-tuned yeast surface-display/secretion platform enables the rapid discovery of neutralizing antibodies against Clostridioides difficile toxins. Microb Cell Fact. 2023;22(1):194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10519002</ArticleId><ArticleId IdType="pubmed">37749574</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiotto T, et al. Nanobodies mapped to cross-reactive and divergent epitopes on A(H7N9) influenza hemagglutinin using yeast display. Sci Rep. 2021;11(1):3126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7862619</ArticleId><ArticleId IdType="pubmed">33542302</ArticleId></ArticleIdList></Reference><Reference><Citation>Ming K, et al. Development of nanobodies against Staphylococcus enterotoxin B through yeast surface display. Int J Biol Macromol. 2023;253: 126822.</Citation><ArticleIdList><ArticleId IdType="pubmed">37703983</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleetwood F, et al. Surface display of a single-domain antibody library on Gram-positive bacteria. Cell Mol Life Sci. 2013;70(6):1081–93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11113301</ArticleId><ArticleId IdType="pubmed">23064703</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavallari M. Rapid and direct VHH and target identification by staphylococcal surface display libraries. Int J Mol Sci. 2017;18(7):1507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5535997</ArticleId><ArticleId IdType="pubmed">28704956</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanes J, Jermutus L, Pluckthun A. Selecting and evolving functional proteins in vitro by ribosome display. Methods Enzymol. 2000;328:404–30.</Citation><ArticleIdList><ArticleId IdType="pubmed">11075357</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Liu R. Advantages of mRNA display selections over other selection techniques for investigation of protein-protein interactions. Expert Rev Proteomics. 2011;8(3):335–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7103729</ArticleId><ArticleId IdType="pubmed">21679115</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari D, et al. A novel nanobody scaffold optimized for bacterial expression and suitable for the construction of ribosome display libraries. Mol Biotechnol. 2020;62(1):43–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">31720928</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan V, Zhang F, Dahlman JE. Drug delivery systems for CRISPR-based genome editors. Nat Rev Drug Discov. 2023;22(11):875–94.</Citation><ArticleIdList><ArticleId IdType="pubmed">37723222</ArticleId></ArticleIdList></Reference><Reference><Citation>Landberg J, et al. CRISPR interference of nucleotide biosynthesis improves production of a single-domain antibody in Escherichia coli. Biotechnol Bioeng. 2020;117(12):3835–48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7818426</ArticleId><ArticleId IdType="pubmed">32808670</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo F, et al. Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy. Signal Transduct Target Ther. 2021;6(1):80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7904846</ArticleId><ArticleId IdType="pubmed">33627635</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng C, et al. Split-Cas9-based targeted gene editing and nanobody-mediated proteolysis-targeting chimeras optogenetically coordinated regulation of Survivin to control the fate of cancer cells. Clin Transl Med. 2023;13(8): e1382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10449816</ArticleId><ArticleId IdType="pubmed">37620295</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross FR, et al. Expanding and improving nanobody repertoires using a yeast display method: targeting SARS-CoV-2. J Biol Chem. 2023; 299(3).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9884143</ArticleId><ArticleId IdType="pubmed">36720309</ArticleId></ArticleIdList></Reference><Reference><Citation>Hambach J, et al. Targeting CD38-expressing multiple myeloma and burkitt lymphoma cells in vitro with nanobody-based chimeric antigen receptors (Nb-CARs). Cells. 2020;9(2):321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7072387</ArticleId><ArticleId IdType="pubmed">32013131</ArticleId></ArticleIdList></Reference><Reference><Citation>Hambach J, et al. Half-life extended nanobody-based CD38-specific bispecific killercell engagers induce killing of multiple myeloma cells. Front Immunol. 2022;13: 838406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9150782</ArticleId><ArticleId IdType="pubmed">35651607</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseininejad-Chafi M, et al. Development of a functional nanobody targeting programmed cell death protein-1 as immune checkpoint inhibitor. Curr Pharm Des. 2023;29(29):2336–44.</Citation><ArticleIdList><ArticleId IdType="pubmed">37859326</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitsch P, et al. Penetration of nanobody-dextran polymer conjugates through tumor spheroids. Pharmaceutics. 2023;15(10):2374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10609859</ArticleId><ArticleId IdType="pubmed">37896133</ArticleId></ArticleIdList></Reference><Reference><Citation>Deken MM, et al. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. J Control Release. 2020;323:269–81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116241</ArticleId><ArticleId IdType="pubmed">32330574</ArticleId></ArticleIdList></Reference><Reference><Citation>Barough MS, et al. Anti–MUC1 nanobody can synergize the Tamoxifen and Herceptin effects on breast cancer cells by inducing ER, PR and HER2 overexpression. Int Immunopharmacol. 2023;124: 110792.</Citation><ArticleIdList><ArticleId IdType="pubmed">37633239</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, et al. A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells. Front Immunol. 2023;14:1292839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10634241</ArticleId><ArticleId IdType="pubmed">37954614</ArticleId></ArticleIdList></Reference><Reference><Citation>Arvindam US, et al. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Leukemia. 2021;35(6):1586–96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8189652</ArticleId><ArticleId IdType="pubmed">33097838</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan X, et al. Optimized silk fibroin nanoparticle functionalization with anti-CEA nanobody enhancing active targeting of colorectal cancer cells. Biomed Mater. 2023; 18(4).</Citation><ArticleIdList><ArticleId IdType="pubmed">37321227</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Tourneau C, et al. Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors. ESMO Open. 2022;7(5): 100576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9588896</ArticleId><ArticleId IdType="pubmed">36108560</ArticleId></ArticleIdList></Reference><Reference><Citation>Roshan R, et al. Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy. Mol Immunol. 2021;129:70–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">33183767</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasiri F, Safarzadeh Kozani P, Rahbarizadeh F. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts. Front Immunol. 2023;14:1063838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9978144</ArticleId><ArticleId IdType="pubmed">36875091</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaneycken I, et al. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/Micro-CT. J Nucl Med. 2010;51(7):1099–106.</Citation><ArticleIdList><ArticleId IdType="pubmed">20554727</ArticleId></ArticleIdList></Reference><Reference><Citation>Khirehgesh MR, et al. Design and construction a novel humanized biparatopic nanobody-based immunotoxin against epidermal growth factor receptor (EGFR). J Drug Delivery Sci Technol. 2021;66: 102837.</Citation></Reference><Reference><Citation>Zhu X-Y, et al. A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity. Acta Pharmacol Sin. 2024;45(3):609–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10834580</ArticleId><ArticleId IdType="pubmed">38030799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao C, et al. The application of nanobody in CAR-T therapy. Biomolecules. 2021;11(2):238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7914546</ArticleId><ArticleId IdType="pubmed">33567640</ArticleId></ArticleIdList></Reference><Reference><Citation>Safarzadeh Kozani P, et al. Nanobody-based CAR-T cells for cancer immunotherapy. Biomark Res. 2022;10(1):24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9036779</ArticleId><ArticleId IdType="pubmed">35468841</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma. Clin Cancer Res. 2022;28(13):2830–43.</Citation><ArticleIdList><ArticleId IdType="pubmed">35435984</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia B, et al. Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment. Mol Ther Oncolytics. 2023;30:86–102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10427987</ArticleId><ArticleId IdType="pubmed">37593111</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020;135(10):713–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7059518</ArticleId><ArticleId IdType="pubmed">31951650</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, et al. Camel nanobody-based B7–H3 CAR-T cells show high efficacy against large solid tumours. Nat Commun. 2023;14(1):5920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10517151</ArticleId><ArticleId IdType="pubmed">37739951</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie YJ, et al. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci. 2019;116(16):7624–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6475367</ArticleId><ArticleId IdType="pubmed">30936321</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, et al. Envafolimab–first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors. Expert Opin Biol Ther. 2022;22(10):1227–32.</Citation><ArticleIdList><ArticleId IdType="pubmed">36124972</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassanzadeh Eskafi A, et al. Investigation of the therapeutic potential of recombinant bispecific bivalent anti-PD-L1/VEGF nanobody in inhibition of angiogenesis. Immunopharmacol Immunotoxicol. 2023;45(2):197–202.</Citation><ArticleIdList><ArticleId IdType="pubmed">36193665</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, et al. A PD-L1xCD3 bispecific nanobody as a novel T-cell engager in treating PD-L1 overexpression melanoma. Mol Immunol. 2023;163:20–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">37722180</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan J, et al. A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models. Signal Transduct Target Ther. 2021;6(1):320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8413295</ArticleId><ArticleId IdType="pubmed">34475375</ArticleId></ArticleIdList></Reference><Reference><Citation>Toffoli EC, et al. Enhancement of NK cell antitumor effector functions using a bispecific single domain antibody targeting CD16 and the epidermal growth factor receptor. Cancers (Basel). 2021;13(21):5446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8582566</ArticleId><ArticleId IdType="pubmed">34771609</ArticleId></ArticleIdList></Reference><Reference><Citation>Narbona J, et al. Nanobody-Based EGFR-targeting immunotoxins for colorectal cancer treatment. Biomolecules. 2023; 13(7).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10377705</ArticleId><ArticleId IdType="pubmed">37509078</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela-Nieto G, et al. Nanobodies: COVID-19 and future perspectives. Front Drug Discovery. 2022;2: 927164.</Citation></Reference><Reference><Citation>Aria H, et al. Outlook of therapeutic and diagnostic competency of nanobodies against SARS-CoV-2: a systematic review. Anal Biochem. 2022;640: 114546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8730734</ArticleId><ArticleId IdType="pubmed">34995616</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, et al. A naive phage display library-derived nanobody neutralizes SARS-CoV-2 and three variants of concern. Int J Nanomedicine. 2023;18:5781–95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10588750</ArticleId><ArticleId IdType="pubmed">37869063</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao H, et al. A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses, including all major Omicron strains. MedComm. 2023;4(6): e397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10600506</ArticleId><ArticleId IdType="pubmed">37901798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H, et al. Potent neutralization of SARS-CoV-2 by hetero-bivalent alpaca nanobodies targeting the spike receptor-binding domain. J Virol. 2021;95(10):10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139655</ArticleId><ArticleId IdType="pubmed">33658349</ArticleId></ArticleIdList></Reference><Reference><Citation>Gai J, et al. A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential. MedComm. 2021;2(1):101–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013425</ArticleId><ArticleId IdType="pubmed">33821254</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye G, et al. Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19. J Virol. 2023;97(11):e01448-e1523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10688364</ArticleId><ArticleId IdType="pubmed">37855638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya M, et al. Therapeutic applications of nanobodies against SARS-CoV-2 and other viral infections: current update. Int J Biol Macromol. 2023;229:70–80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9797221</ArticleId><ArticleId IdType="pubmed">36586649</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauhar A, et al. Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro. Faseb J. 2021;35(11): e21970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8667653</ArticleId><ArticleId IdType="pubmed">34637549</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, Q., et al., Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein. Cells, 2022. 11(21).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9656363</ArticleId><ArticleId IdType="pubmed">36359751</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim H, et al. Single-domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. Biomed Eng Adv. 2022;4:100054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9482557</ArticleId><ArticleId IdType="pubmed">36158162</ArticleId></ArticleIdList></Reference><Reference><Citation>Mast FD, et al. Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. Elife. 2021;10: e73027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8651292</ArticleId><ArticleId IdType="pubmed">34874007</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha-Santos C, et al. Inhibition of HIV replication through siRNA carried by CXCR4-targeted chimeric nanobody. Cell Mol Life Sci. 2020;77:2859–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11104913</ArticleId><ArticleId IdType="pubmed">31641784</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham S, et al. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(1):21–32.</Citation><ArticleIdList><ArticleId IdType="pubmed">33002427</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadbent L. et al. Comparative therapeutic potential of ALX-0171 and palivizumab against respiratory syncytial virus clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures. Antimicrob Agents Chemother, 2020; 64(2).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985719</ArticleId><ArticleId IdType="pubmed">31767728</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei Y, et al. Research progress and applications of nanobody in human infectious diseases. Front Pharmacol. 2022;13: 963978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9411660</ArticleId><ArticleId IdType="pubmed">36034845</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmen W, et al. A single nanobody neutralizes multiple epochally evolving human noroviruses by modulating capsid plasticity. Nat Commun. 2023;14(1):6516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10579229</ArticleId><ArticleId IdType="pubmed">37845211</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders N, et al. TMPRSS2 is a functional receptor for human coronavirus HKU1. Nature. 2023;624:207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11331971</ArticleId><ArticleId IdType="pubmed">37879362</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietrich MH, et al. Nanobodies against Pfs230 block Plasmodium falciparum transmission. Biochem J. 2022;479(24):2529–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9788556</ArticleId><ArticleId IdType="pubmed">36520108</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J, et al. Characterization and applications of nanobodies against Pseudomonas aeruginosa Exotoxin A selected from single alpaca B cells. Biotechnol Biotechnol Equip. 2020;34(1):1028–37.</Citation></Reference><Reference><Citation>Wouters Y, et al. Identification and in vivo characterization of a brain-penetrating nanobody. Fluids Barriers CNS. 2020;17(1):62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556960</ArticleId><ArticleId IdType="pubmed">33054787</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino M, Holt MG. AAV vector-mediated antibody delivery (A-MAD) in the central nervous system. Front Neurol. 2022;13: 870799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9039256</ArticleId><ArticleId IdType="pubmed">35493843</ArticleId></ArticleIdList></Reference><Reference><Citation>Marino M, et al. AAV-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer’s disease model. EMBO Mol Med. 2022;14(4): e09824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8988209</ArticleId><ArticleId IdType="pubmed">35352880</ArticleId></ArticleIdList></Reference><Reference><Citation>Bélanger K, et al. Single-domain antibodies as therapeutic and imaging agents for the treatment of CNS diseases. Antibodies. 2019;8(2):27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6640712</ArticleId><ArticleId IdType="pubmed">31544833</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, et al. Multivalent nanobody conjugate with rigid, reactive oxygen species scavenging scaffold for multi-target therapy of Alzheimer’s disease. Adv Mater. 2023;35(17): e2210879.</Citation><ArticleIdList><ArticleId IdType="pubmed">36786375</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang MS, et al. Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer’s disease therapeutic. J Cereb Blood Flow Metab. 2022;42(5):788–801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9014686</ArticleId><ArticleId IdType="pubmed">34378436</ArticleId></ArticleIdList></Reference><Reference><Citation>Abskharon R, et al. Structure-based design of nanobodies that inhibit seeding of Alzheimer’s patient–extracted tau fibrils. Proc Natl Acad Sci. 2023;120(41): e2300258120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10576031</ArticleId><ArticleId IdType="pubmed">37801475</ArticleId></ArticleIdList></Reference><Reference><Citation>Danis C, et al. Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment. Mol Ther. 2022;30(4):1484–99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9077319</ArticleId><ArticleId IdType="pubmed">35007758</ArticleId></ArticleIdList></Reference><Reference><Citation>Monti G, et al. Epitope mapping of nanobodies binding the Alzheimer’s disease receptor SORLA. J Biotechnol. 2023;375:17–27.</Citation><ArticleIdList><ArticleId IdType="pubmed">37634829</ArticleId></ArticleIdList></Reference><Reference><Citation>Leemans M, et al. Allosteric modulation of the GTPase activity of a bacterial LRRK2 homolog by conformation-specific Nanobodies. Biochem J. 2020;477(7):1203–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135905</ArticleId><ArticleId IdType="pubmed">32167135</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh RK, et al. Nanobodies as allosteric modulators of Parkinson’s disease–associated LRRK2. Proc Natl Acad Sci. 2022;119(9): e2112712119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8892280</ArticleId><ArticleId IdType="pubmed">35217606</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler YR, et al. alpha-Synuclein fibril-specific nanobody reduces prion-like alpha-synuclein spreading in mice. Nat Commun. 2022;13(1):4060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9296447</ArticleId><ArticleId IdType="pubmed">35853942</ArticleId></ArticleIdList></Reference><Reference><Citation>Hmila I, et al. Novel engineered nanobodies specific for N-terminal region of alpha-synuclein recognize Lewy-body pathology and inhibit in-vitro seeded aggregation and toxicity. FEBS J. 2022;289(15):4657–73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9545584</ArticleId><ArticleId IdType="pubmed">35090199</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar MS, et al. Anti-SOD1 nanobodies that stabilize misfolded SOD1 proteins also promote neurite outgrowth in mutant SOD1 human neurons. Int J Mol Sci. 2022;23(24):16013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9784173</ArticleId><ArticleId IdType="pubmed">36555655</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilodi M, et al. Selection and modelling of a new single-domain intrabody against TDP-43. Front Mol Biosci. 2021;8: 773234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8884700</ArticleId><ArticleId IdType="pubmed">35237655</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoebl P, et al. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2020;18(2):479–84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7027866</ArticleId><ArticleId IdType="pubmed">31691462</ArticleId></ArticleIdList></Reference><Reference><Citation>Palanques-Pastor T, et al. Effectiveness of caplacizumab nanobody in acquired thrombotic thrombocytopenic purpura refractory to conventional treatment. Acta Haematol. 2022;145(1):72–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">34352748</ArticleId></ArticleIdList></Reference><Reference><Citation>Estcourt LJ. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial). Transfus Med. 2019;29(3):146–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31318128</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavriilaki E, et al. Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data. Front Med (Lausanne). 2023;10:1226114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10600458</ArticleId><ArticleId IdType="pubmed">37901415</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakawa Y, et al. The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study. Int J Hematol. 2023;117(3):366–77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9970947</ArticleId><ArticleId IdType="pubmed">36427162</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully M, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335–46.</Citation><ArticleIdList><ArticleId IdType="pubmed">30625070</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully M, et al. Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: post-HERCULES study. J Thromb Haemost. 2022;20(12):2810–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9827931</ArticleId><ArticleId IdType="pubmed">36138517</ArticleId></ArticleIdList></Reference><Reference><Citation>Volker LA, et al. Five years of caplacizumab—lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura. J Thromb Haemost. 2023;21(10):2718–25.</Citation><ArticleIdList><ArticleId IdType="pubmed">37562668</ArticleId></ArticleIdList></Reference><Reference><Citation>Arce NA, et al. Activation of von Willebrand factor via mechanical unfolding of its discontinuous autoinhibitory module. Nat Commun. 2021;12(1):2360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8060278</ArticleId><ArticleId IdType="pubmed">33883551</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HT, et al. High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP. Biochem Biophys Res Commun. 2021;567:49–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">34144500</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, et al. Efficacy and safety of anti-TNF multivalent NANOBODY® compound ‘ozoralizumab’without methotrexate co-administration in patients with active rheumatoid arthritis: a 52-week result of phase III, randomised, open-label trial (NATSUZORA trial). Mod Rheumatol. 2023;33(5):875–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">36201360</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, et al. Efficacy and safety of the anti-TNF multivalent NANOBODY(R) compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 52-week result of a Phase II/III study (OHZORA trial). Mod Rheumatol. 2023;33(5):883–90.</Citation><ArticleIdList><ArticleId IdType="pubmed">36197757</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi T, et al. Phase II/III results of a trial of anti-tumor necrosis factor multivalent NANOBODY compound ozoralizumab in patients with rheumatoid arthritis. Arthritis Rheumatol. 2022;74(11):1776–85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9828347</ArticleId><ArticleId IdType="pubmed">35729713</ArticleId></ArticleIdList></Reference><Reference><Citation>Svecova D, et al. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis. J Am Acad Dermatol. 2019;81(1):196–203.</Citation><ArticleIdList><ArticleId IdType="pubmed">30926369</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp KA, et al. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021;397(10284):1564–75.</Citation><ArticleIdList><ArticleId IdType="pubmed">33894834</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, et al. Improved production of anti-FGF-2 nanobody using pichia pastoris and its effect on antiproliferation of keratinocytes and alleviation of psoriasis. Arch Immunol Ther Exp (Warsz). 2023;71(1):20.</Citation><ArticleIdList><ArticleId IdType="pubmed">37632545</ArticleId></ArticleIdList></Reference><Reference><Citation>Gesiorowski A, et al. Bispecific soluble cytokine receptor-nanobody fusions inhibit Interleukin (IL-)6 trans-signaling and IL-12/23 or tumor necrosis factor (TNF) signaling. J Biol Chem. 2023;299(11): 105343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10652096</ArticleId><ArticleId IdType="pubmed">37838173</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch JP, et al. Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut. Cell Host Microbe. 2023;31(4):634–49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10101937</ArticleId><ArticleId IdType="pubmed">37003258</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R, et al. Identification and characterization of a novel nanobody against human CTGF to reveal its antifibrotic effect in an in vitro model of liver fibrosis. Int J Nanomed. 2023;18:5407–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10519214</ArticleId><ArticleId IdType="pubmed">37753068</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Campenhout R, et al. Nanobody-based pannexin1 channel inhibitors reduce inflammation in acute liver injury. J Nanobiotechnol. 2023;21(1):371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10566086</ArticleId><ArticleId IdType="pubmed">37821897</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao G, et al. Nanobody-functionalized conduit with built-in static mixer for specific elimination of cytokines in hemoperfusion. Acta Biomater. 2023;172:260–71.</Citation><ArticleIdList><ArticleId IdType="pubmed">37806373</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, et al. Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma. Respir Res. 2022;23(1):316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9675287</ArticleId><ArticleId IdType="pubmed">36403040</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailon Calderon H, et al. Development of nanobodies against hemorrhagic and myotoxic components of bothrops atrox snake venom. Front Immunol. 2020;11:655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7224310</ArticleId><ArticleId IdType="pubmed">32457735</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilmes M, et al. Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions. J Neuroinflammation. 2022;19(1):256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9559872</ArticleId><ArticleId IdType="pubmed">36224611</ArticleId></ArticleIdList></Reference><Reference><Citation>Struijf EM, et al. Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies. J Biol Chem. 2023;299(8): 104956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10374974</ArticleId><ArticleId IdType="pubmed">37356719</ArticleId></ArticleIdList></Reference><Reference><Citation>Barakat S, et al. Nanobodies as molecular imaging probes. Free Radical Biol Med. 2022;182:260–75.</Citation><ArticleIdList><ArticleId IdType="pubmed">35240292</ArticleId></ArticleIdList></Reference><Reference><Citation>de Beer MA, Giepmans BNG. Nanobody-based probes for subcellular protein identification and visualization. Front Cell Neurosci. 2020;14: 573278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7667270</ArticleId><ArticleId IdType="pubmed">33240044</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin X, et al. Development of novel-nanobody-based lateral-flow immunochromatographic strip test for rapid detection of recombinant human interferon alpha2b. J Pharm Anal. 2022;12(2):308–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9091920</ArticleId><ArticleId IdType="pubmed">35582401</ArticleId></ArticleIdList></Reference><Reference><Citation>Glassman PM, et al. Molecularly engineered nanobodies for tunable pharmacokinetics and drug delivery. Bioconjug Chem. 2020;31(4):1144–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7413641</ArticleId><ArticleId IdType="pubmed">32167754</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji F, et al. Nanobodies: from serendipitous discovery of heavy chain-only antibodies in camelids to a wide range of useful applications. Methods Mol Biol. 2022;2446:3–17.</Citation><ArticleIdList><ArticleId IdType="pubmed">35157266</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng F, et al. Applications of nanobodies in brain diseases. Front Immunol. 2022;13:978513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9679430</ArticleId><ArticleId IdType="pubmed">36426363</ArticleId></ArticleIdList></Reference><Reference><Citation>Leopold AV, Shcherbakova DM, Verkhusha VV. Fluorescent biosensors for neurotransmission and neuromodulation: engineering and applications. Front Cell Neurosci. 2019;13:474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6819510</ArticleId><ArticleId IdType="pubmed">31708747</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Yuan J, Jiang C. Applications of nanobodies in plant science and biotechnology. Plant Mol Biol. 2021;105(1–2):43–53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7547553</ArticleId><ArticleId IdType="pubmed">33037986</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakri AM, et al. Generation and characterization of nanobodies against tomato leaf curl sudan virus. Plant Dis. 2021;105(9):2410–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">33599515</ArticleId></ArticleIdList></Reference><Reference><Citation>Gettemans J. Site-specific fluorescent labeling, single-step immunocytochemistry, and delivery of nanobodies into living cells. In: Single-domain antibodies: methods and protocols. Springer; 2022. p. 373–93.</Citation><ArticleIdList><ArticleId IdType="pubmed">35157284</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrants H, et al. Chemogenetic control of nanobodies. Nat Methods. 2020;17(3):279–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">32066961</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu K, et al. Development of nanobody-horseradish peroxidase-based sandwich ELISA to detect Salmonella Enteritidis in milk and in vivo colonization in chicken. J Nanobiotechnology. 2022;20(1):167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8973953</ArticleId><ArticleId IdType="pubmed">35361208</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. Enhancing oriented immobilization efficiency: a one-for-two organism-bispecific nanobody scaffold for highly sensitive detection of foodborne pathogens. Anal Chem. 2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">37941297</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu ML, et al. A bispecific nanobody with high sensitivity/efficiency for simultaneous determination of carbaryl and its metabolite 1-naphthol in the soil and rice samples. Environ Pollut. 2023;335: 122265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10529271</ArticleId><ArticleId IdType="pubmed">37517641</ArticleId></ArticleIdList></Reference><Reference><Citation>De Greve H, et al. Simplified monomeric VHH-Fc antibodies provide new opportunities for passive immunization. Curr Opin Biotechnol. 2020;61:96–101.</Citation><ArticleIdList><ArticleId IdType="pubmed">31810049</ArticleId></ArticleIdList></Reference><Reference><Citation>De Munter S, et al. Rapid and effective generation of nanobody based CARs using PCR and gibson assembly. Int J Mol Sci. 2020;21(3):883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7037261</ArticleId><ArticleId IdType="pubmed">32019116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassani M, et al. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer. J Cell Biochem. 2019;120(6):10787–95.</Citation><ArticleIdList><ArticleId IdType="pubmed">30672018</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang EY, Shah K. Nanobodies: next generation of cancer diagnostics and therapeutics. Front Oncol. 2020;10:1182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390931</ArticleId><ArticleId IdType="pubmed">32793488</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocancia-Mateescu L-A, et al. Nanobodies as diagnostic and therapeutic tools for cardiovascular diseases (CVDs). Pharmaceuticals. 2023;16(6):863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10301117</ArticleId><ArticleId IdType="pubmed">37375810</ArticleId></ArticleIdList></Reference><Reference><Citation>Harmsen MM, et al. Single-domain antibody multimers for detection of botulinum neurotoxin serotypes C, D, and their mosaics in endopep-MS. Toxins. 2023;15(9):573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10535107</ArticleId><ArticleId IdType="pubmed">37755999</ArticleId></ArticleIdList></Reference><Reference><Citation>Xavier C, et al. Synthesis, preclinical validation, dosimetry, and toxicity of &lt;sup&gt;68&lt;/sup&gt;Ga-NOTA-Anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med. 2013;54(5):776–84.</Citation><ArticleIdList><ArticleId IdType="pubmed">23487015</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrynchak I, et al. Nanobody-based theranostic agents for HER2-positive breast cancer: radiolabeling strategies. Int J Mol Sci. 2021;22(19):10745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8509594</ArticleId><ArticleId IdType="pubmed">34639086</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda R, et al. A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. Commun Biol. 2022;5(1):669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9257560</ArticleId><ArticleId IdType="pubmed">35794202</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordus SL, et al. Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo. PLoS Pathog. 2023;19(10):e1011496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10621975</ArticleId><ArticleId IdType="pubmed">37871122</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, et al. Identification of serum ferritin-specific nanobodies and development towards a diagnostic immunoassay. Biomolecules. 2022;12(8):1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9406126</ArticleId><ArticleId IdType="pubmed">36008974</ArticleId></ArticleIdList></Reference><Reference><Citation>Arce LP, et al. A multispecies competitive nanobody-based ELISA for the detection of antibodies against hepatitis E virus. Sci Rep. 2023;13(1):15448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10507121</ArticleId><ArticleId IdType="pubmed">37723180</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, et al. Highly sensitive detection of CTLA-4-positive T-cell subgroups based on nanobody and fluorescent carbon quantum dots. Oncol Lett. 2019;18(1):109–16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6540141</ArticleId><ArticleId IdType="pubmed">31289479</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, et al. Construction of immunomagnetic particles with high stability in stringent conditions by site-directed immobilization of multivalent nanobodies onto bacterial magnetic particles for the environmental detection of tetrabromobisphenol-A. Anal Chem. 2020;92(1):1114–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9484546</ArticleId><ArticleId IdType="pubmed">31763820</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Yanez F, et al. Fast one-step ultrasensitive detection of toxocara canis antigens by a nanobody-based electrochemical magnetosensor. Anal Chem. 2019;91(18):11582–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31429269</ArticleId></ArticleIdList></Reference><Reference><Citation>Sánchez-Salcedo R, et al. Comparing nanobody and aptamer-based capacitive sensing for detection of interleukin-6 (IL-6) at physiologically relevant levels. Anal Bioanalytical Chem. 2023;415:7035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10684427</ArticleId><ArticleId IdType="pubmed">37794245</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghumra DP, et al. Rapid direct detection of SARS-CoV-2 aerosols in exhaled breath at the point of care. ACS sensors. 2023;8(8):3023–31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10463275</ArticleId><ArticleId IdType="pubmed">37498298</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo K, et al. Rapid single-molecule detection of COVID-19 and MERS antigens via nanobody-functionalized organic electrochemical transistors. Nat Biomed Eng. 2021;5(7):666–77.</Citation><ArticleIdList><ArticleId IdType="pubmed">34031558</ArticleId></ArticleIdList></Reference><Reference><Citation>Keyaerts M, et al. Phase II trial of HER2-PET/CT using 68Ga-anti-HER2 VHH1 for characterization of HER2 presence in brain metastases of breast cancer patients. Ann Oncol. 2019;30:iii25–6.</Citation></Reference><Reference><Citation>Ma J, et al. CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin. Biomater Res. 2022;26(1):64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9701387</ArticleId><ArticleId IdType="pubmed">36435809</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, et al. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking. Theranostics. 2022;12(12):5551–63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9330517</ArticleId><ArticleId IdType="pubmed">35910795</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, et al. Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga] Ga-nanobody: from bench to bedside. Eur J Nucl Med Mol Imaging. 2023;50:3735.</Citation><ArticleIdList><ArticleId IdType="pubmed">37382662</ArticleId></ArticleIdList></Reference><Reference><Citation>Altunay B, et al. 99mTc-labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types. Eur J Nucl Med Mol Imaging. 2023;50(4):1005–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931776</ArticleId><ArticleId IdType="pubmed">36482076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lecocq Q, et al. Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer. EJNMMI Res. 2021;11(1):115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8563901</ArticleId><ArticleId IdType="pubmed">34727262</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeven K, et al. Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT. Front Immunol. 2023;14:1268900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10548220</ArticleId><ArticleId IdType="pubmed">37799715</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayn S, et al. Site-specifically conjugated single-domain antibody successfully identifies glypican-3-expressing liver cancer by immuno-PET. J Nucl Med. 2023;64(7):1017–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10315705</ArticleId><ArticleId IdType="pubmed">36997331</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. Pilot study of a novel nanobody (68) Ga-NODAGA-SNA006 for instant PET imaging of CD8(+) T cells. Eur J Nucl Med Mol Imaging. 2022;49(13):4394–405.</Citation><ArticleIdList><ArticleId IdType="pubmed">35829748</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng F, et al. NIRF-molecular imaging with synovial macrophages-targeting Vsig4 nanobody for disease monitoring in a mouse model of arthritis. Int J Mol Sci. 2019;20(13):3347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6651725</ArticleId><ArticleId IdType="pubmed">31288389</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes D, et al. SPECT/CT using [99mTc]-labeled anti-programmed death-ligand 1 (PD-L1) single-domain antibody (NM-01) to predict response to immune checkpoint inhibition in non-small cell lung cancer: preliminary results from the PD-L1 Expression in Cancer (PECan) study. 2022, Soc Nuclear Med.</Citation></Reference><Reference><Citation>Yang Y, et al. Dose escalation biodistribution, positron emission tomography/computed tomography imaging and dosimetry of a highly specific radionuclide-labeled non-blocking nanobody. EJNMMI Res. 2021;11(1):113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8557220</ArticleId><ArticleId IdType="pubmed">34718889</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv G, et al. PET imaging of tumor PD-L1 expression with a highly specific nonblocking single-domain antibody. J Nucl Med. 2020;61(1):117–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6954462</ArticleId><ArticleId IdType="pubmed">31253743</ArticleId></ArticleIdList></Reference><Reference><Citation>Xavier C, et al. Clinical translation of [(68)Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT imaging of protumorigenic macrophages. Mol Imaging Biol. 2019;21(5):898–906.</Citation><ArticleIdList><ArticleId IdType="pubmed">30671739</ArticleId></ArticleIdList></Reference><Reference><Citation>Varasteh Z, et al. Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 68 Ga-NOTA-anti-MMR nanobody: non-invasive imaging of atherosclerotic plaques. EJNMMI Res. 2019;9:1–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6340911</ArticleId><ArticleId IdType="pubmed">30666513</ArticleId></ArticleIdList></Reference><Reference><Citation>Gondry O, et al. Phase I study of [(68)Ga]Ga-Anti-CD206-sdAb for PET/CT assessment of protumorigenic macrophage presence in solid tumors (MMR Phase I). J Nucl Med. 2023;64(9):1378–84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10478821</ArticleId><ArticleId IdType="pubmed">37474271</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing Y, et al. Early phase I study of a (99m)Tc-labeled anti-programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non-small cell lung cancer. J Nucl Med. 2019;60(9):1213–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6735283</ArticleId><ArticleId IdType="pubmed">30796165</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, et al. Labeling single domain antibody fragments with fluorine-18 using 2,3,5,6-tetrafluorophenyl 6-[(18)F]Fluoronicotinate resulting in high tumor-to-kidney ratios. Mol Pharm. 2019;16(1):214–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6465114</ArticleId><ArticleId IdType="pubmed">30427188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertveldt T, et al. Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8(+) T cell and iNKT cell activating mRNA vaccine. Theranostics. 2023;13(15):5483–500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10614673</ArticleId><ArticleId IdType="pubmed">37908728</ArticleId></ArticleIdList></Reference><Reference><Citation>Pant K, et al. Active targeting of dendritic polyglycerols for diagnostic cancer imaging. Small. 2020;16(7): e1905013.</Citation><ArticleIdList><ArticleId IdType="pubmed">31880080</ArticleId></ArticleIdList></Reference><Reference><Citation>Montemagno C, et al. 99mTc-A1 as a novel imaging agent targeting mesothelin-expressing pancreatic ductal adenocarcinoma. Cancers. 2019;11(10):1531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6827014</ArticleId><ArticleId IdType="pubmed">31658755</ArticleId></ArticleIdList></Reference><Reference><Citation>Benloucif A, et al. Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies. Front Immunol. 2023;14:1200652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10303918</ArticleId><ArticleId IdType="pubmed">37388728</ArticleId></ArticleIdList></Reference><Reference><Citation>Broos K, et al. Evaluating a single domain antibody targeting human PD-L1 as a nuclear imaging and therapeutic agent. Cancers. 2019;11(6):872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6628009</ArticleId><ArticleId IdType="pubmed">31234464</ArticleId></ArticleIdList></Reference><Reference><Citation>Senders ML, et al. Nanobody-facilitated multiparametric PET/MRI phenotyping of atherosclerosis. JACC Cardiovasc Imaging. 2019;12(10):2015–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6461528</ArticleId><ArticleId IdType="pubmed">30343086</ArticleId></ArticleIdList></Reference><Reference><Citation>Jailkhani N, et al. Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix. Proc Natl Acad Sci U S A. 2019;116(28):14181–90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6628802</ArticleId><ArticleId IdType="pubmed">31068469</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyaert J, Kobilka BK. Nanobody stabilization of G protein-coupled receptor conformational states. Curr Opin Struct Biol. 2011;21(4):567–72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166880</ArticleId><ArticleId IdType="pubmed">21782416</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchanski T, Pardon E, Steyaert J. Nanobodies to study protein conformational states. Curr Opin Struct Biol. 2020;60:117–23.</Citation><ArticleIdList><ArticleId IdType="pubmed">32036243</ArticleId></ArticleIdList></Reference><Reference><Citation>Frecot DI, Froehlich T, Rothbauer U. 30 years of nanobodies–an ongoing success story of small binders in biological research. J Cell Sci. 2023;136(21):jcs261395.</Citation><ArticleIdList><ArticleId IdType="pubmed">37937477</ArticleId></ArticleIdList></Reference><Reference><Citation>Dmitriev OY, Lutsenko S, Muyldermans S. Nanobodies as probes for protein dynamics in vitro and in cells. J Biol Chem. 2016;291(8):3767–75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4759159</ArticleId><ArticleId IdType="pubmed">26677230</ArticleId></ArticleIdList></Reference><Reference><Citation>Limbocker R, et al. Rationally designed antibodies as research tools to study the structure–toxicity relationship of amyloid-β oligomers. Int J Mol Sci. 2020;21(12):4542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7352524</ArticleId><ArticleId IdType="pubmed">32630615</ArticleId></ArticleIdList></Reference><Reference><Citation>Harmansa S, et al. A nanobody-based toolset to investigate the role of protein localization and dispersal in Drosophila. Elife. 2017; 6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5388529</ArticleId><ArticleId IdType="pubmed">28395731</ArticleId></ArticleIdList></Reference><Reference><Citation>Bothma JP, et al. LlamaTags: a versatile tool to image transcription factor dynamics in live embryos. Cell. 2018;173(7):1810–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6003873</ArticleId><ArticleId IdType="pubmed">29754814</ArticleId></ArticleIdList></Reference><Reference><Citation>Loreau V, et al. A nanobody toolbox to investigate localisation and dynamics of Drosophila titins and other key sarcomeric proteins. Elife. 2023; 12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9886281</ArticleId><ArticleId IdType="pubmed">36645120</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang H, Gao Y, Han J. Application progress of the single domain antibody in medicine. Int J Mol Sci. 2023;24(4):4176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9967291</ArticleId><ArticleId IdType="pubmed">36835588</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu D, et al. Optogenetic activation of intracellular antibodies for direct modulation of endogenous proteins. Nat Methods. 2019;16(11):1095–100.</Citation><ArticleIdList><ArticleId IdType="pubmed">31611691</ArticleId></ArticleIdList></Reference><Reference><Citation>Pomeranz L, et al. Magnetogenetic cell activation using endogenous ferritin. bioRxiv, 2023.</Citation></Reference><Reference><Citation>Katz HE. Antigen sensing via nanobody-coated transistors. Nat Biomed Eng. 2021;5(7):639–40.</Citation><ArticleIdList><ArticleId IdType="pubmed">34272521</ArticleId></ArticleIdList></Reference><Reference><Citation>Koklu A, et al. Convection driven ultrarapid protein detection via nanobody-functionalized organic electrochemical transistors. Adv Mater. 2022;34(35): e2202972.</Citation><ArticleIdList><ArticleId IdType="pubmed">35772173</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, et al. Specific detection of proteins by a nanobody-functionalized nanopore sensor. ACS Nano. 2023;17(10):9167–77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10184537</ArticleId><ArticleId IdType="pubmed">37127291</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirao A, et al. Design of single-domain VHH antibodies to increase the binding activity in SPR amine coupling. Biochem Biophys Res Commun. 2023;663:54–60.</Citation><ArticleIdList><ArticleId IdType="pubmed">37119766</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao KS, et al. Synthetic nanobodies as tools to distinguish IgG Fc glycoforms. Proc Natl Acad Sci. 2022;119(48): e2212658119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9860306</ArticleId><ArticleId IdType="pubmed">36409896</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi X, et al. A novel shark single-domain antibody targeting OGT as a tool for detection and intracellular localization. Front Immunol. 2023;14:1062656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9968394</ArticleId><ArticleId IdType="pubmed">36855630</ArticleId></ArticleIdList></Reference><Reference><Citation>Jailkhani N, et al. Proteomic profiling of extracellular matrix components from patient metastases identifies consistently elevated proteins for developing nanobodies that target primary tumors and metastases. Can Res. 2023;83(12):2052–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10267678</ArticleId><ArticleId IdType="pubmed">37098922</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, et al. Improved sensitivity of the anti-microcystin-LR ELISA using phage-displayed alpha-type anti-idiotypic nanobody. Anal Biochem. 2023;664: 115030.</Citation><ArticleIdList><ArticleId IdType="pubmed">36572217</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen-Duc T, et al. Nanobody®-based chromatin immunoprecipitation/micro-array analysis for genome-wide identification of transcription factor DNA binding sites. Nucleic Acids Res. 2013;41(5):e59–e59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3597646</ArticleId><ArticleId IdType="pubmed">23275538</ArticleId></ArticleIdList></Reference><Reference><Citation>Momin N, et al. Maximizing response to intratumoral immunotherapy in mice by tuning local retention. Nat Commun. 2022;13(1):109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8748612</ArticleId><ArticleId IdType="pubmed">35013154</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Toribio A, et al. Direct injection of functional single-domain antibodies from E. coli into human cells. PLoS ONE. 2010;5(12):e15227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2999559</ArticleId><ArticleId IdType="pubmed">21170340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz EA, et al. Intratumoral nanobody-IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice. PNAS Nexus. 2022;1(5):pgac244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9802395</ArticleId><ArticleId IdType="pubmed">36712341</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaleghi S, Rahbarizadeh F, Nikkhoi SK. Anti-HER2 VHH targeted fluorescent liposome as bimodal nanoparticle for drug delivery and optical imaging. Recent Pat Anti-Cancer Drug Discovery. 2021;16(4):552–62.</Citation><ArticleIdList><ArticleId IdType="pubmed">34365930</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesquita BS, et al. The impact of nanobody density on the targeting efficiency of PEGylated liposomes. Int J Mol Sci. 2022;23(23):14974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9741042</ArticleId><ArticleId IdType="pubmed">36499301</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin W, et al. BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFRT790M mutation. Theranostics. 2020;10(14):6122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255027</ArticleId><ArticleId IdType="pubmed">32483443</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham TC, et al. Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery. J Extracell Vesicles. 2021;10(4): e12057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7886705</ArticleId><ArticleId IdType="pubmed">33643546</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu S, et al. A nanobody-mediated virus-targeting drug delivery platform for the central nervous system viral disease therapy. Microbiol Spectr. 2021;9(3): e0148721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8612154</ArticleId><ArticleId IdType="pubmed">34817277</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik JA, et al. Nano-drug delivery system: a promising approach against breast cancer. Ther Deliv. 2023;14(5):357–81.</Citation><ArticleIdList><ArticleId IdType="pubmed">37431741</ArticleId></ArticleIdList></Reference><Reference><Citation>Banihashemi SR, et al. Liposome-based nanocarriers loaded with anthrax lethal factor and armed with anti-CD19 VHH for effectively inhibiting MAPK pathway in B cells. Int Immunopharmacol. 2021;100: 107927.</Citation><ArticleIdList><ArticleId IdType="pubmed">34500284</ArticleId></ArticleIdList></Reference><Reference><Citation>Awad RM, et al. Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade. Mol Ther Methods Clin Dev. 2021;22:172–82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8397838</ArticleId><ArticleId IdType="pubmed">34485603</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva-Pilipich N, et al. Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses. Cancer Lett. 2023;561: 216139.</Citation><ArticleIdList><ArticleId IdType="pubmed">37001752</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki Y, et al. Lactobacilli as a vector for delivery of nanobodies against norovirus infection. Pharmaceutics. 2023;15(1):63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9863548</ArticleId><ArticleId IdType="pubmed">36678692</ArticleId></ArticleIdList></Reference><Reference><Citation>Gangaiah D, et al. Recombinant Limosilactobacillus (Lactobacillus) delivering nanobodies against Clostridium perfringens NetB and alpha toxin confers potential protection from necrotic enteritis. Microbiologyopen. 2022;11(2): e1270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8924699</ArticleId><ArticleId IdType="pubmed">35478283</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, et al. Nanobody Nb6 fused with porcine IgG Fc as the delivering tag to inhibit porcine reproductive and respiratory syndrome virus replication in porcine alveolar macrophages. Vet Res. 2021;52:1–14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887809</ArticleId><ArticleId IdType="pubmed">33596995</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamann MV, et al. Improved targeting of human CD4+ T cells by nanobody-modified AAV2 gene therapy vectors. PLoS ONE. 2021;16(12): e0261269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8687595</ArticleId><ArticleId IdType="pubmed">34928979</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M, et al. Advanced genetic engineering to achieve in vivo targeting of adenovirus utilizing camelid single domain antibody. J Control Release. 2021;334:106–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10292108</ArticleId><ArticleId IdType="pubmed">33872627</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison C. Nanobody approval gives domain antibodies a boost. Nat Rev Drug Discov. 2019;18(7):485–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31267082</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollifield AL, Arnall JR, Moore DC. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura. Am J Health Syst Pharm. 2020;77(15):1201–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32588878</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard A. FDA approves second BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov. 2022;21(4):249.</Citation><ArticleIdList><ArticleId IdType="pubmed">35277677</ArticleId></ArticleIdList></Reference><Reference><Citation>Keam SJ. Ozoralizumab: first approval. Drugs. 2023;83(1):87–92.</Citation><ArticleIdList><ArticleId IdType="pubmed">36509938</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y, et al. DR30303, a SMART-VHHBody powered anti-CLDN18. 2 VHH-Fc with enhanced ADCC activity for the treatment of gastric and pancreatic cancers. Cancer Res. 2022;82(12_Supplement):2857–2857.</Citation></Reference><Reference><Citation>Yamamoto N, et al. Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2023;91(6):469–80.</Citation><ArticleIdList><ArticleId IdType="pubmed">37140602</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu T, et al. Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors. Invest New Drugs. 2022;40(5):1021–31.</Citation><ArticleIdList><ArticleId IdType="pubmed">35932387</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14(1):95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8218452</ArticleId><ArticleId IdType="pubmed">34154614</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulos KP, et al. First-in-human phase I study of envafolimab, a novel subcutaneous single-domain anti-PD-L1 antibody, in patients with advanced solid tumors. Oncologist. 2021;26(9):e1514–25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8417852</ArticleId><ArticleId IdType="pubmed">33973293</ArticleId></ArticleIdList></Reference><Reference><Citation>D’Huyvetter M, et al. Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients. J Nucl Med. 2021;62(8):1097–105.</Citation><ArticleIdList><ArticleId IdType="pubmed">33277400</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramlau R, et al. P2. 06-006 Phase I/II dose escalation study of L-DOS47 as a monotherapy in non-squamous non-small cell lung cancer patients: topic: phase I/II trials. J Thoracic Oncol. 2017;12(1):S1071–2.</Citation></Reference><Reference><Citation>Piha-Paul S, et al. A phase 1, open-label, dose-escalation study of L-DOS47 in combination with pemetrexed plus carboplatin in patients with stage IV recurrent or metastatic nonsquamous NSCLC. JTO Clin Res Rep. 2022;3(11): 100408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9576893</ArticleId><ArticleId IdType="pubmed">36268537</ArticleId></ArticleIdList></Reference><Reference><Citation>Kater AP, et al. Lava-051, a novel bispecific gamma-delta T-cell engager (Gammabody), in relapsed/refractory MM and CLL: pharmacodynamic and early clinical data. Blood. 2022;140(Supplement 1):4608–9.</Citation></Reference><Reference><Citation>Mehra N, et al. Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC). 2023, American Society of Clinical Oncology.</Citation></Reference><Reference><Citation>Martin T, et al. Updated results from CARTITUDE-1: phase 1b/2Study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Blood. 2021;138:549.</Citation><ArticleIdList><ArticleId IdType="pubmed">34175021</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdeja JG, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–24.</Citation><ArticleIdList><ArticleId IdType="pubmed">34175021</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao WH, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022;15(1):86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9261106</ArticleId><ArticleId IdType="pubmed">35794616</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Donk N, et al. B07: safety and efficacy of ciltacabtagene autoleucel, a chimeric antigen receptor t-cell therapy directed against b-cell maturation antigen in patients with multiple myeloma and early relapse after initial therapy: cartitude-2 results. HemaSphere. 2022;6:9–10.</Citation></Reference><Reference><Citation>Einsele H, et al. P08: CARTITUDE-2 UPDATE: Ciltacabtagene autoleucel, a b-cell maturation antigen–directed chimeric antigen receptor T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1–3 prior lines of therapy. Hemasphere. 2022;6:15.</Citation></Reference><Reference><Citation>Cohen YC, et al. Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a b-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1–3 prior lines of therapy: Updated results from CARTITUDE-2. Blood. 2021;138:3866.</Citation></Reference><Reference><Citation>Agha ME, et al. S185: CARTITUDE-2 cohort B: updated clinical data and biological correlative analyses of ciltacabtagene autoleucel in patients with multiple myeloma and early relapse after initial therapy. HemaSphere. 2022;6:86–7.</Citation></Reference><Reference><Citation>Brussel, U.Z. Quantification of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Metastasis of Breast Carcinoma Patients and Assessment of Repeatability (VUBAR)—Pilot Study. ClinicalTrials.gov identifier: NCT03924466. September 10, 2024]; Available from: https://clinicaltrials.gov/study/NCT03924466?a=3.</Citation></Reference><Reference><Citation>Alexion Pharmaceuticals, I., A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis. ClinicalTrial.gov Identifier: NCT05556096.</Citation></Reference><Reference><Citation>Muyldermans S. Applications of nanobodies. Annu Rev Anim Biosci. 2021;9:401–21.</Citation><ArticleIdList><ArticleId IdType="pubmed">33233943</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, et al. Nanobody: a small antibody with big implications for tumor therapeutic strategy. Int J Nanomedicine. 2021;16:2337–56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7997558</ArticleId><ArticleId IdType="pubmed">33790553</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackaert C, et al. Immunogenicity risk profile of nanobodies. Front Immunol. 2021;12: 632687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7985456</ArticleId><ArticleId IdType="pubmed">33767701</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossotti MA, et al. Immunogenicity and humanization of single-domain antibodies. FEBS J. 2022;289(14):4304–27.</Citation><ArticleIdList><ArticleId IdType="pubmed">33751827</ArticleId></ArticleIdList></Reference><Reference><Citation>van Leeuwen FW, et al. Trending: radioactive and fluorescent bimodal/hybrid tracers as multiplexing solutions for surgical guidance. J Nucl Med. 2020;61(1):13–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31712326</ArticleId></ArticleIdList></Reference><Reference><Citation>Messer A, Butler DC. Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders. Neurobiol Dis. 2020;134: 104619.</Citation><ArticleIdList><ArticleId IdType="pubmed">31669671</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdés-Tresanco MS, et al. Structural modeling of nanobodies: a benchmark of state-of-the-art artificial intelligence programs. Molecules. 2023;28(10):3991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10220908</ArticleId><ArticleId IdType="pubmed">37241731</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, et al. Opportunities and challenges for antibodies against intracellular antigens. Theranostics. 2019;9(25):7792–806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6831482</ArticleId><ArticleId IdType="pubmed">31695801</ArticleId></ArticleIdList></Reference><Reference><Citation>Awad RM, et al. Emerging applications of nanobodies in cancer therapy. Int Rev Cell Mol Biol. 2022;369:143–99.</Citation><ArticleIdList><ArticleId IdType="pubmed">35777863</ArticleId></ArticleIdList></Reference><Reference><Citation>Wouters Y, et al. VHHs as tools for therapeutic protein delivery to the central nervous system. Fluids Barriers CNS. 2022;19(1):1–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9531356</ArticleId><ArticleId IdType="pubmed">36192747</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Numair NS, et al. Camels’ biological fluids contained nanobodies: promising avenue in cancer therapy. Cancer Cell Int. 2022;22(1):279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9449263</ArticleId><ArticleId IdType="pubmed">36071488</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowden MJ, et al. Applications of high-throughput DNA sequencing to single-domain antibody discovery and engineering. Methods Mol Biol. 2023;2702:489–540.</Citation><ArticleIdList><ArticleId IdType="pubmed">37679637</ArticleId></ArticleIdList></Reference><Reference><Citation>Arras P, et al. AI/ML combined with next-generation sequencing of VHH immune repertoires enables the rapid identification of de novo humanized and sequence-optimized single domain antibodies: a prospective case study. Front Mol Biosci. 2023;10:1249247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10575757</ArticleId><ArticleId IdType="pubmed">37842638</ArticleId></ArticleIdList></Reference><Reference><Citation>Laustsen AH, et al. Animal immunization, in vitro display technologies, and machine learning for antibody discovery. Trends Biotechnol. 2021;39(12):1263–73.</Citation><ArticleIdList><ArticleId IdType="pubmed">33775449</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabbitts T. Intracellular antibodies for drug discovery and as drugs of the future. Antibodies. 2023;12(1):24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10044824</ArticleId><ArticleId IdType="pubmed">36975371</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X, et al. Shark IgNAR: the next broad application antibody in clinical diagnoses and tumor therapies? Mar Drugs. 2023;21(9):496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10532743</ArticleId><ArticleId IdType="pubmed">37755109</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamers-Casterman C, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8502296</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmyter A, et al. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat Struct Biol. 1996;3(9):803–11.</Citation><ArticleIdList><ArticleId IdType="pubmed">8784355</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo J, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020;27(9):846–54.</Citation><ArticleIdList><ArticleId IdType="pubmed">32661423</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbabi-Ghahroudi M. Camelid single-domain antibodies: historical perspective and future outlook. Front Immunol. 2017;8:1589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5701970</ArticleId><ArticleId IdType="pubmed">29209322</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>